In the past decade, many countries in Asia, in particularly in East Asia, are experiencing a progressive rise in the incidence and prevalence of inflammatory bowel disease (IBD). Improved physician awareness and diagnostic methods are unlikely to fully account for this rapid increase. This epidemiological shift is likely to relate to industralization, westernization of lifestyles and changes in eating habits, as part of the socioeconomic development in Asia, although many of these putative environmental factors have not been formally investigated in Asian cohorts. Genetic factors for IBD differ between Asia and the West. NOD2/CARD15 mutation, repeatedly observed in the Caucasian populations, is not associated with Crohn's disease in Asian populations. Familial clustering is generally uncommon in Asia but it is expected to increase as the IBD prevalence in this region rises. Ethnic-racial differences of IBD have been described and Indians appear to be most affected in South-East Asia. Clinical manifestation of IBD in Asia resemble the Western population in general, but with some differences, including higher prevalence of males and ileocolonic disease, lower disease severity, surgical rates and extraintestinal manifestations. These differences may relate to time factor, genetic background and environmental factors. This review summarises recent epidemiological data of IBD including environmental factors associated with the development of IBD in Asia. Future research focusing on studying the epidemiology of IBD in an area of rapidly increasing prevalence such as Asia will allow the opportunity to identify potential risk factors and provide a better understanding of the aetiology of disease in the Asian population. (Intest Res 2010;8:1-8)
BACKGROUND
Crohn's disease (CD) and Ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) of unknown aetiology. The pathophysiology of IBD relates to a dysregulated mucosal immune response to antigenic stimulation from gut microbiota on a background of genetic susceptibility. 1 IBD represents an important public health problem because it affects mostly young people at an age when they are most active in their private and professional lives, 2 and a management challenge because of its unpredictable relapsing nature. During the last few decades the incidence of IBD has changed in many ways. Incidence rates of traditionally high incidence areas such as Western Europe is relatively stable or even decreasing, 3 while diseases have become more prevalent in previously low incidence areas, such as Asia and Eastern Europe. [4] [5] [6] [7] The reason for these changes remains unknown. They are unlikely to be merely increased awareness of the disease and differences in diagnostic practices, but most likely reflect real differences secondary to environmental factors, lifestyle changes and genetic factors. 8 Genetic susceptibility is different in Asian compared to Western patients. 7 Apart from geographic differences, ethnic differences have been described in multi-racial countries including Malaysia and Singapore. Indians appeared to be more susceptible to IBD than Chinese and native Malays. 9 Half the world's population reside in the Asia-Pacific region and the continuing rise in incidence of IBD will have important implications for health care providers in many Asian countries who will need to address both health needs of patients and the social burden of these chronic diseases. [10] [11] [12] [13] The epidemiology and clinical characteristics of IBD in Asia has been recently reviewed in two comprehensive reviews, 7, 14 and consensus for the management of IBD from several counties in Asia Asia has been published. [15] [16] [17] [18] In this paper, I have provided an update on the incidence and prevalence of IBD, and susceptibility genes identified to date in studies from Asia. Environmental factors that may play a role in the rising incidence of IBD in this region were reviewed. Clinical features and complications of IBD in Asia were compared with the West, and clinical challenges and future research questions were discussed.
INCIDENCE AND PREVALENCE
The incidence rates of CD and UC vary worldwide between 0.1 to 16 per 100,000 inhabitants and 0.5 to 24.5 per 100,000 inhabitants, respectively. 19, 20 IBD is more common in the Northern than the Southern part of the world, and it is more common among Caucasian compared with non-caucasian populations. The highest incidence rates have been recorded in North America and North and West Europe, while lower rates have been reported in South America, Africa and Asia. 21 The incidence of IBD in Australia has recently been shown to equal to the highest in the world. 22 Epidemiological studies in the West have shown that the increase in incidence of UC precedes the increase of incidence of CD by about 15 to 20 years. [23] [24] [25] In Asia, several studies have indicated a rising trend of the incidence and prevalence of IBD although only few data are available on the true epidemiology of IBD in Asia. 7 Studies reporting the incidence of IBD in Asia have been derived mostly from hospital based database in which confirmed cases of IBD were extrapolated to the area that the hospital serves with the population in that area used as a denominator. Japan is the only country in Asia that has a national IBD registry maintained by the Ministry of Health, Labour and Welfare. Data reporting time trend increase in the incidence of IBD in Asia are now available. [26] [27] [28] [29] In Japan, cumulative numbers of IBD patients has risen by three-fold. The estimated annual incidence of CD in Japan have increased from approximately 0.6 per 100,000 in 1986 to 1.2 per 100,000 population in 1998. 30 In Hong Kong, there is a three-fold increase in the incidence of CD in Chinese patients from 0.3 per 100,000 in 1986 to 1 per Only very few population-based IBD studies exist in the Asian population. One study in India performed a community based survey in random selected districts in Punjab and reported a crude incidence for UC of 6.02 cases per 100,000 inhabitants. 32 This figure is likely to be an underestimation of the true prevalence of UC as not all patients had a sigmoidoscopy or biopsy to confirm disease. Another population-based study in Korea has shown a steady rise in the mean annual incidence of CD and UC in the Songpa-Kangdong district of Seoul from 0.05 and 0.34 per 100,000 inhabitants, respectively, in 1986-1990 to 1.34 and 3.08 per 100,000 inhabitants, respectively, in 2001-2005. 27 In countries of multi-ethnic population such as Singapore and Malaysia, Indians have a higher prevalence of UC and CD than Chinese and Malays. [33] [34] [35] Overall, published studies in Asia have confirmed that the incidence and prevalence of both UC and CD are increasing in Asia although the reported rates are still lower that in North America and Europe. There is also a time lag phenomenon compared to time trends in the West. Table 1 shows the incidence and prevalence of CD and UC from studies derived mostly from East Asia and South-East Asia. Table 2 shows the genetic susceptibility loci in Asian IBD patients. Compared with Caucasians, familial clustering for both CD and UC is rare in Asian patients. 7, 9, 62 A family history of IBD has been reported in up to 3% and 10% of UC and CD patients in Asian studies. [27] [28] [29] 33, 40, 63 This lower rates of familial aggregration in Asia is most likely related to the overall low disease prevalence, and as disease prevalence increases with time, the attributable risk of a positive family history is likely to be similar in Asian and Caucasian patients. 64 
GENETICS

ENVIRONMENTAL FACTORS
Changes in lifestyle in Asia during the last two decades have resulted in a more "westernized" standard way of living, with increased consumption of refined sugar, fatty acids, fast food, cereals and bread and reduced consumption of fruit, vegetables and fibres. 82, 83 With all of these aspects of westernization previously being associated with IBD, 84, 85 westernization of lifestyle could potentially explain the observed increases of incidence of UC and CD. 20, 82, 86 In Japan, the increased intake of diary products and meat has paralleled the rising trend of UC, 29 and a higher consumption of sweets and high fat diet has been associated with UC and CD. 87 Other more controversial risk factors such as tonsillectomy, perinatal infections, oral contraceptives, breastfeeding and vaccinations have been proposed as being associated with IBD, but these factors have not been studied in the Asian cohorts. The only factors that have been proven to be important environmental factors in both UC and CD in studies from the West are smoking and appendectomy. Small studies in East Asia however have not shown an association between smoking and CD. 28, 88 Conversely the protective effect of smoking on UC had been confirmed in studies from Japan and China. 37, 89 Consistent with Western data, case-control studies in Asia has demonstrated the protective effect of appendectomy in UC. 89, 90 Overall, Asian populations probably has genetic susceptibility, that when exposed to putative environmental factors will develop IBD. This predisposition appears to be stronger in certain racial groups.
CLINICAL CHARACTERISTICS
Clinical manifestation of IBD in Asia is relatively similar to that of the West although disease severity may be less in Asia. A few studies have reported differences in the clinical phenotypes and complications of IBD, including higher prevalence of ileocolonic involvement in CD, lower surgical rates, and a low frequency of primary sclerosing cholangitis among IBD patients in Asia. 7, 14 Differences in disease, severity and complications may relate to genetic background, environmental factos such as diet and intestinal flora, and the duration of disease. 7 The peak age of disease onset in Asia is 20 to 50 years, and a second peak after 50 years old is less common in Asian patients. 91 Combined small and large bowel involvement appears to be most common in East Asia. In South and West Asia, distribution of disease site is more variable. 9, 27, 62 Extraintestinal manifestations are less common in Asian populations. 
CURRENT CHALLENGES AND FUTURE DIRECTIONS
Current major clinical challenge relates to the accurate diagnosis of IBD in countries with a high background prevalence of infections. The diagnosis of CD in geographical areas where tuberculosis is common poses a diagnostic challenge. Infections may mimic IBD, and can complicate the course of existing IBD. Limited availability of diagnostic tests in particularly radiological imaging may delay diagnosis. Screening for latent infections specifically for tuberculosis and hepatitis B deserve special consideration in Asia given the high prevalence of these diseases in the Asian populations. Recently biological theapy has entered the armamentarium of IBD, and the efficacy and side effects of biologics in Asian cohorts warrant further investigations. There is also a diverse medical practice in South Asia and South East Asia which include alternative and complementary medicine, Ayurveda, Homeopathy, and some patients with IBD may prefer to present to traditional and alternative health practitioners.
With the exception of Japan, Asia currently lacks population based registries of IBD. Contraints in health care resources have made the conduct of an epidemiological study in developing countries a challenge. Larger epidemiological data over time are necessary to describe the true incidence of IBD and further characterize the clinical features and risk factors of IBD in different geographical areas in the Asia-Pacific region. The conduct of an epidemiology study in Asia requires good case ascertainment in a well defined area with known denominator. Such studies will better define the burden of illness, explore the mechanism of association with environmental factors as well as identify new risk factors. Future studies to determine whether smoking plays a lesser role in the development of CD in Asian populations are needed. Studying exposure and risk factors for IBD require prospectivey collected data from questionnaires on diet and environmental exposure in order to minimise recall bias and incomplete data. A large scale web-based epidemiology study (EpiCOM) organised by the European Crohn's and Colitis Organisation (ECCO) is currently in progress in East and West Europe. A second project known as the Origin study, also onducted by ECCO, aims to prospectively recruit first degree relatives of probands with CD and follow them for at least ten years to assess the genotype, gut microbiota, immune function biomarkers and enviromental exposures of subjects at risk of developing IBD.
Most genetic variants associated with IBD identified in Asia so far, through fine-mapping and candidate gene approach, vary according to ethnicity and nationalities. There is a lack of Genome wide association studies in Asia, and to identify novel Asian IBD-associated genes, such a study will require collaborative efforts between various centres in Asia in order to collect large number of samples. If the genetic and clinical heterogeneity of IBD in Asia is different from Western populations, response to medical therapy may also be different in our patients.
IBD represents an important public health problem affecting both the patient's education, working abilities, social life and quality of life. Apart from direct medical costs associated with hospitalisations and surgery, IBD is associated with substantial indirect costs related to activity impairment, especially since the onset of IBD typically occurs during adulthood. Little is also currently known of the cost of management of IBD in Asia. 91 More likely than not, the incidence of IBD will continue to surge in Asia in the next decade. Effective research and development of IBD therapies will require network and collaboration between multiple centres in Asia. Although yet incorporated into practice in Asia, optimal patient management will need to move towards multi-disciplinary approach, including the active involvement of specialist dietitions, radiologist, surgeons, and in some tertiary IBD centres, IBD nurse specialist and psycologists. New systems and opportunities for education in IBD should be incorporated into training of specialists.
CONCLUSION
The rising incidence of IBD in Asia in the last two decades is a real phenomenon, which is considered to be the result of environmental changes secondary to economic growth and affluence. There appears to be variation in the incidence, prevalence and disease characterisitics between Asians of different nationalities and geography. Well conducted epidemiological studies of IBD will not only inform health care policy of the true scale of the disease in Asia but also offer the opportunity to help clinicians and researchers elucidate the role of enviromental factors and identify new aetiological factors responsible for this "IBD epidemic" in Asia.
